.Attribute Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ sophisticated bosom cancer cells and also active or even stable human brain metastases revealed consistent intracranial activity as well as systemic efficiency of T-DXd.